Dr. Baranov has more than 20 years’ experience in cancer research and in other biotech-related areas for the last 15 years. He is an innovator for applications of physical chemistry and biophysical methods in vivo and holds five U.S. patents for inventions. He has published more than 60 papers in highly-ranked scientific journals such as Cell, Cancer Cell and Proceedings of the National Academy of Sciences of the USA (PNAS). He has presented results of his research at over 30 conferences and seminars worldwide. Dr. Baranov has been an educator at several international universities. He was also a consultant for several U.S. companies specializing in cancer research, nutrition and cosmetics. 

Dr. Baranov’s research has been significant in uncovering the anthracycline drugs molecular mechanism of action on the cellular level; the development of vital fluorescent dye and laser-based technology for early cancer diagnosis in clinical practice; the implementation of a double derivative method for data image analysis of collagen structure in normal and pathological tissues (breast cancer and diabetes); the application of fluorescent, polarized and nanosecond time-resolved spectroscopy for drug interactions with their molecular targets; and the use of GFP-based technique for whole body tumor quantitative imaging and gene expression. 

Dr. Baranov has been overseeing preclinical and clinical studies internationally as well as technology transfer for Stemedica since its inception in 2005 in the areas of testing efficacy and safety of biologically active compounds; various types of stem cells and their derived products in diverse types of pathologies; disorders and cosmetology; and in regenerative medicine.